Media Center
Press Releases
06 Apr 18

Back to posts

Asia-Pacific hereditary angioedema (HAE) therapeutics market will exceed $100m by 2023, says GBI Research

The HAE therapeutics market across the Asia-Pacific (APAC) region, which includes India, China, Australia, South Korea and Japan, is set to rise from $54.5m in 2016 to $103.5m in 2023, representing a compound annual growth rate (CAGR) of 9.6%, according to business intelligence provider GBI Research.

The company’s latest report states that the prevalence of HAE in APAC markets is low, it is gradually rising and impacts more women than men. The overall healthy years lost in APAC because of HAE have been steadily growing.

The diagnosed prevalence population of the five APAC countries is set to grow during the forecast period, predominantly due to an increase in the awareness of the disease and increasing overall population. Rising life expectancies will result in a higher lifetime cost of drug treatment, owing to the disease’s chronic and incurable nature.

Nagarjuna, Senior Analyst for GBI Research, says that currently treatment algorithms for HAE have not been greatly diversified due to the rarity of the disease and high R&D costs associated with drug development even though orphan drug assistance programs exist in few countries. The market is mainly reliant on plasma derivatives, recombinant products and synthetic peptides that compete for the same sub-population of HAE patients, namely those who are refractory to generic drugs such as danazol, stanozolol and tranexamic acid. Fresh Frozen Plasma (FFP) is the preferred treatment option in these countries for acute attacks of HAE due to affordability issue and lack of proper orphan drug policies in place mainly in India and China. However, despite of developments in recent years, there remains a significant unmet need in terms of drug profile safety, RoA convenience and drugs that can achieve cure.

Nagarjuna continues: “Although the HAE treatment regimen is currently dominated by highly priced plasma derivatives, recombinant products and synthetic peptides. In the near future, the use of mAbs would become part of the treatment regimen for some patients.”
The late-stage HAE pipeline have only three products, composed of blood/plasma derivatives, mAbs and other proteins targeting C1 esterases and kallikreins. C1 esterase inhibitors and kallikrein remains the mainstay of HAE treatment due to their superior efficacy and minimal the adverse side effects make this treatment suitable for long-term use. However, there is a huge unmet need in terms of therapy cost.

The introduction of re-formulations of existing plasma derivatives with subcutaneous route of administration for HAE in APAC region, will significantly change the treatment landscape for HAE patients, as these can be self-administered at home with minimal training, which avoids a visit to the hospital and additional costs that are associated with intravenous route of administration.

The pipeline molecules SHP-616 and CSL-830 are expected to address some of the unmet needs in the HAE market. These will likely be considered an alternative to the current therapies for patients with HAE, offering the benefit of subcutaneous route of administration, as opposed to intravenous injection, as with the current premium therapies. These drugs expected hit the market in 2018 in Japan and Australia.

Information based on the GBI Research report: HAE Therapeutics in Asia-Pacific Markets to 2023 - Growth Driven by Ongoing Shift towards Plasma-Derivative Products and Expected Launch of Premium Therapies



GBI Research is a market-leading provider of business intelligence reports,offering actionable data and forecasts based on the insights of key industry leaders to ensure you stayup-to-date with the latest emerging trends in your markets.

For further details, please Contact Us.

Latest Press Releases


Send this to a colleague

I have read and accept terms and conditions and privacy policy